π Eli Lilly $LLY surges on Q2 earnings beat and raised 2026 guidance β Mounjaro unstoppable
Lilly opened today on a high after reporting Q2 results that topped both EPS and revenue estimates, then raised its full-year outlook for the second consecutive quarter. Mounjaro has grabbed 60%+ of the GLP-1 market with revenue soaring 125% last quarter, and the company now targets 2026 revenue well above its prior $82β85B guidance range. Not financial advice. Does Lilly still have room to run, or is the GLP-1 trade getting crowded?
β‘ 6 buzzing
206 views
π 0 subscribed